Researchers at four U.S. universities are starting a clinical trial to test varying strengths of a vaccine designed to fight avian influenza.
The multicenter trial will test a modified form of an investigational bird flu vaccine to determine whether the vaccine triggers a strong immune response at lower doses.
The 7-month trial is sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Participating in the study are the University of Maryland, the University of Rochester, Baylor College of Medicine and the Duke University Medical Center.
Copyright 2006 by United Press International
Related stories:
New vaccine to fight multiple vaccine strains
A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.
Personalized immunotherapy to fight HIV/AIDS
For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team's findings were presented on August 5 at the XVII International AIDS Conference in Mexico City.
Nano vaccine for hepatitis B shows promise for third world
Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.
Plants make vaccine for treating type of cancer
Plants could act as safe, speedy factories for growing antibodies for personalized treatments against a common form of cancer, according to new findings from the Stanford University School of Medicine. The findings came in the first human tests of an injectable vaccine grown in genetically engineered plants.
Vaccine for koala chlamydia close
Professors Peter Timms and Ken Beagley from Queensland University of Technology's Institute of Health and Biomedical Innovation (IHBI) said the vaccinated koalas, which are at Brisbane's Lone Pine Koala Sanctuary, were mounting a good response to the vaccine.
Researchers: Program discourages HIV transmission in Russia
(Boston)-Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found that sexual behavior counseling during drug addiction treatment should be considered an important component among Russian substance-dependent individuals, in order to decrease risky sexual behavior in the HIV at-risk population. This study appears in the journal
Addiction.
UF scientists to work with German firm in prostate cancer treatment research
University of Florida department of urology officials signed an agreement Tuesday to collaborate with the German biopharmaceutical company CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment.
Researchers discover significant efficacy of travelers' diarrhea vaccine
Researchers at The University of Texas School of Public Health have found that patients given a travelers' diarrhea vaccine were significantly less likely to suffer from clinically significant diarrhea than those who received placebo, according to a study published in this week's edition of the Lancet. The patch-based vaccine is part of the Phase 2 study in conjunction with the Iomai Corporation.